Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, was featured in a recent MidasLetter Livepodcast. Mydecine’s CEO and Chairman Joshua Bartch joined the program to provide an overview of the company and the science behind its psychedelic compounds. “What we are showing in the efficacy rates that are coming out of that study are over three to five times what’s currently available of Chantix or a nicotine patch with a much safer drug,” Bartch said in discussing clinical trials for smoking cessation using psilocybin.
“It’s a much more effective drug. When you look at the total addressable market it’s projected to be $64.5 billion by 2026, so that report gave us a 0.5% of the overall addressable market… So given the upside potential of one of our drugs being successful, you’re looking at a multiple dollar stock at a bare minimum. These are blockbuster drug potentials.”
To view the full podcast, visit https://ibn.fm/phugd
About Mydecine Innovations Group
Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure.
Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential.
By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are viewed. Mydecine’s vision is to bridge the current gap between what the mental healthcare system currently provides with the needs of the patients. For more information about the company, please visit www.Mydecine.com.
NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at http://ibn.fm/MYCOF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.